Date: 2016-02-05
Type of information: Nomination
Compound:
Company: Sanofi (France)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On February 5, 2016, Sanofi announced the appointment of Muzammil \"Muz\" Mansuri as a new member of the Executive Committee, effective February 22, 2016. Mr. Mansuri joins Sanofi from Gilead Sciences and will take the position of Executive Vice President, Strategy & Business Development. Mr. Mansuri will be responsible for all Group strategic planning, business development, strategic intelligence, alliance management and the Sanofi Genzyme Bio Ventures fund. A dual citizen of the U.S. and United Kingdom, Mr. Mansuri has more than 35 years of experience beginning in 1981 with Shell Research Limited where he began as a research scientist. After Shell, he spent several years with BMS in various R&D roles with increasing responsibility. From 2007 to 2010, Mr. Mansuri was Chairman and CEO at CGI Pharmaceuticals. Mr. Mansuri\'s most recently was Senior Vice President, Research & Development Strategy and Corporate Development at Gilead Sciences. Mr. Mansuri holds a Bachelor of Science degree in Chemistry and a Ph.D in Organic Chemistry from the University College London. He held post-doctoral positions at the University of California, Los Angeles (UCLA) and Columbia University.
Financial terms:
Latest news:
